This article reviews recent successes in the development of safe and effective antiviral therapy for rhinoviruses and enteroviruses.
Highlights progress in rhinovirus/enterovirus antivirals; leaves open clinical adoption pending prospective trials.
The picornaviruses are a diverse group of viral pathogens that together comprise the most common causes of infection of humans in the developed world. Within the picornavirus family are three well-known groups of human pathogens--the rhinoviruses, the enteroviruses (including polioviruses, coxsackieviruses and echoviruses) and the hepatoviruses (including hepatitis A virus). This article will focus on the rhinoviruses and enteroviruses, agents for which substantial effort has been expended, and recent successes reported, toward the development of safe and effective antiviral therapy.
No takes yet. Share an insight, caveat, or question.
Harley A. Rotbart (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: